ATE258799T1 - Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort - Google Patents

Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort

Info

Publication number
ATE258799T1
ATE258799T1 AT98946681T AT98946681T ATE258799T1 AT E258799 T1 ATE258799 T1 AT E258799T1 AT 98946681 T AT98946681 T AT 98946681T AT 98946681 T AT98946681 T AT 98946681T AT E258799 T1 ATE258799 T1 AT E258799T1
Authority
AT
Austria
Prior art keywords
chlorite solution
stabilized chlorite
antigen
immune response
inhibit
Prior art date
Application number
AT98946681T
Other languages
English (en)
Inventor
Frederich W Kuhne
Michael Mcgrath
Boulevard
Edgar G Engleman
Original Assignee
Oxo Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag
Application granted granted Critical
Publication of ATE258799T1 publication Critical patent/ATE258799T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT98946681T 1997-10-06 1998-10-06 Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort ATE258799T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6095397P 1997-10-06 1997-10-06
PCT/IB1998/001676 WO1999017787A2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Publications (1)

Publication Number Publication Date
ATE258799T1 true ATE258799T1 (de) 2004-02-15

Family

ID=22032774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946681T ATE258799T1 (de) 1997-10-06 1998-10-06 Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort

Country Status (12)

Country Link
US (4) US20050129784A1 (de)
EP (1) EP1021196B1 (de)
JP (1) JP4369615B2 (de)
CN (1) CN1152691C (de)
AT (1) ATE258799T1 (de)
AU (1) AU754928B2 (de)
CA (1) CA2306273A1 (de)
DE (1) DE69821506T2 (de)
DK (1) DK1021196T3 (de)
ES (1) ES2217582T3 (de)
PT (1) PT1021196E (de)
WO (1) WO1999017787A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001724A (es) * 1999-08-18 2004-09-06 Oxo Chemie Ag Soluciones de clorito quimicamente estabilizadas, para tratar cancer y otras enfermedades.
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5371443B2 (ja) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド 亜塩素酸塩製剤、およびこの調製の方法と利用
EP2164502A1 (de) * 2007-06-01 2010-03-24 Dimethaid AG Verwendung von wf10 zur behandlung von allergischem asthma, allergischer rhinitis und atopischer dermatitis
BR112012002333A2 (pt) 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
WO2013109949A1 (en) * 2012-01-19 2013-07-25 Ibt Usa Inc. Therapeutic uses of tetrachlorodecaoxygen (tcdo)
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
WO2014182761A1 (en) * 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
US11813234B2 (en) 2015-08-20 2023-11-14 Oxo Translational Science Gmbh Use of chlorite to treat red blood cell diseases and indications mediated thereby

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574084A (en) * 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5830511A (en) * 1992-06-25 1998-11-03 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
EP2164502A1 (de) * 2007-06-01 2010-03-24 Dimethaid AG Verwendung von wf10 zur behandlung von allergischem asthma, allergischer rhinitis und atopischer dermatitis

Also Published As

Publication number Publication date
ES2217582T3 (es) 2004-11-01
US20120141514A1 (en) 2012-06-07
DE69821506T2 (de) 2004-12-16
DK1021196T3 (da) 2004-06-07
CA2306273A1 (en) 1999-04-15
US20090004295A1 (en) 2009-01-01
JP2001518512A (ja) 2001-10-16
WO1999017787A2 (en) 1999-04-15
US20050129784A1 (en) 2005-06-16
AU754928B2 (en) 2002-11-28
AU9364298A (en) 1999-04-27
CN1152691C (zh) 2004-06-09
EP1021196B1 (de) 2004-02-04
WO1999017787A3 (en) 1999-06-17
DE69821506D1 (de) 2004-03-11
US20110076344A1 (en) 2011-03-31
EP1021196A2 (de) 2000-07-26
JP4369615B2 (ja) 2009-11-25
CN1306433A (zh) 2001-08-01
PT1021196E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
Bloom et al. Selective primary health care: strategies for control of disease in the developing world. V. Leprosy
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
ATE258799T1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
ATE231184T1 (de) Impfstoffe gegen die pest
SE9102808L (sv) Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
ATE64304T1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DE60234115D1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
Undeen et al. Nosema algerae: infection of the white mouse by a mosquito parasite
DE69028320D1 (de) Illudin-analoge, verwendet als antitumormittel
EP0852144A3 (de) Erhöhung der Migration oder Proliferation von Keratinocyten
ATE78403T1 (de) Impfstoff gegen mastitis.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
BR9808878A (pt) Imunização contra moléculas endógenas
Pazdernik et al. Carrier-and hapten-antibody producing cells, in vitro II. Effect of purine antimetabolites
RACIS PROSTAGLANDINS AS PHYSIOLOGICAL IMMUNOREGULATORS (LYMPHOCYTES, HELP, SUPPRESSION, ANTIBODY)
Angelo The woman in the cloth coat.
UA22019A (uk) Спосіб визhачеhhя цитотоксичhості отрути блідої погаhки
ATE167055T1 (de) 4-guanidinobutyramid zur verbesserung des blutkreislaufs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1021196

Country of ref document: EP